Stock Events

Stock Events

TransCode Therapeutics 

$9.03
77
+$0.42+4.82% Today

Statistics

Day High
9.44
Day Low
8.91
52W High
22.04
52W Low
6.08
Volume
4,662
Avg. Volume
250,947
Mkt Cap
8.28M
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

18MayExpected
Q2 2024
Q3 2024
Q1 2025
Q2 2025
Q3 2025
Q4 2025
Next
-56
-37.53
-19.05
-0.58
Expected EPS
N/A
Actual EPS
N/A

Financials

-Profit Margin
Unprofitable
2019
2020
2021
2022
2023
2024
0Revenue
-33.57MNet Income

People Also Follow

This list is based on the watchlists of people on Stock Events who follow RNAZ. It's not an investment recommendation.
Alphabet
79493
GOOGL
Apple
69146
AAPL
Microsoft
64576
MSFT
Amazon
60260
AMZN

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Moderna
MRNA
Mkt Cap10.61B
Moderna, Inc. focuses on mRNA-based therapies, directly competing in the genetic medicines space similar to TransCode's RNA-based treatments.
Alnylam Pharmaceuticals
ALNY
Mkt Cap60.25B
Alnylam Pharmaceuticals, Inc. specializes in RNA interference (RNAi) therapies, targeting the same RNA-based technology approach as TransCode.
Ionis Pharmaceuticals
IONS
Mkt Cap12.03B
Ionis Pharmaceuticals, Inc. develops RNA-targeted therapeutics, making it a direct competitor in the RNA-based drug development field.
Arrowhead Pharmaceuticals
ARWR
Mkt Cap5.86B
Arrowhead Pharmaceuticals, Inc. works on medicines that silence gene expression via RNA interference, competing in the RNA therapy space.
Sarepta Therapeutics
SRPT
Mkt Cap2.51B
Sarepta Therapeutics, Inc. focuses on RNA-targeted drug discovery and development, particularly for rare diseases, similar to TransCode's focus on RNA.
BioNTech
BNTX
Mkt Cap24.99B
BioNTech SE partners with companies to develop mRNA-based drugs for various diseases, competing in the mRNA therapy market.
CRISPR Therapeutics
CRSP
Mkt Cap5.82B
CRISPR Therapeutics AG specializes in gene editing, a different but related field to RNA-based therapies, targeting genetic diseases at the DNA level.
Intellia Therapeutics
NTLA
Mkt Cap1.35B
Intellia Therapeutics, Inc. is involved in CRISPR/Cas9 gene editing, competing in the broader genetic medicine space that includes RNA-based therapies.
Editas Medicine
EDIT
Mkt Cap276.95M
Editas Medicine, Inc. focuses on gene editing using CRISPR technology, representing competition in the genetic medicine arena, including RNA-based approaches.

About

TransCode Therapeutics, Inc., a biopharmaceutical company, engages in the development and commercialization of drugs and diagnostics for treating and identifying metastatic disease. Its lead therapeutic candidate, TTX-MC138, is a preclinical stage product for the treatment of metastatic cancer. The company's products in preclinical programs include TTX-siPDL1, an siRNA-based modulator of programmed death-ligand 1; TTX-siLIN28B, an siRNA-based inhibitor of RNA-binding protein LIN28B. Its cancer agnostic programs comprise TTX-RIGA, an RNA–based agonist of the RIG-I-driven immune response in the tumor microenvironment; TTX-CRISPR, a CRISPR/Cas9–based therapy platform for the repair or elimination of cancer-causing genes inside tumor cells; and TTX-mRNA, an mRNA-based platform for the development of cancer vaccines meant to activate cytotoxic immune responses against tumor cells. The company was incorporated in 2016 and is based in Boston, Massachusetts.
Show more...
CEO
Dr. Philippe P. Calais Ph.D., Pharm., Pharm.D.
Employees
7
Country
US
ISIN
US89357L5012

Listings

XNAS
US
RNAZ
BOATS
BOATS
RNAZ.BOATS

0 Comments

Share your thoughts

FAQ

What is TransCode Therapeutics stock price today?▼
The current price of RNAZ is $9.03 USD — it has increased by +4.82% in the past 24 hours. Watch TransCode Therapeutics stock price performance more closely on the chart.
What is TransCode Therapeutics stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange TransCode Therapeutics stocks are traded under the ticker RNAZ.
Is TransCode Therapeutics stock price growing?▼
RNAZ stock has risen by +4.8% compared to the previous week, the month change is a -6.87% fall, over the last year TransCode Therapeutics has showed a -40.91% decrease.
What is TransCode Therapeutics market cap?▼
Today TransCode Therapeutics has the market capitalization of 8.28M
When is the next TransCode Therapeutics earnings date?▼
TransCode Therapeutics is going to release the next earnings report on May 18, 2026.
What is TransCode Therapeutics revenue for the last year?▼
TransCode Therapeutics revenue for the last year amounts to 0 USD.
What is TransCode Therapeutics net income for the last year?▼
RNAZ net income for the last year is -33.57M USD.
How many employees does TransCode Therapeutics have?▼
As of April 01, 2026, the company has 7 employees.
In which sector is TransCode Therapeutics located?▼
TransCode Therapeutics operates in the Health Care sector.
When did TransCode Therapeutics complete a stock split?▼
The last stock split for TransCode Therapeutics was on May 15, 2025 with a ratio of 1:28.
Where is TransCode Therapeutics headquartered?▼
TransCode Therapeutics is headquartered in Boston, US.